Poster
Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders
This poster details the discovery and validation of fully human anti-ACVR2A antibodies for metabolic and musculoskeletal disorders . Overcoming high species homology via a specialized transgenic platform, it provides comprehensive data on pathway blockade, pharmacokinetics, and in vivo efficacy for improving body composition and muscle function.
Overview
This research presents the successful generation of fully human anti-ACVR2A antibodies—specifically A0009 and A0040—using the HUGO-Ab-eKO platform. Preclinical findings demonstrate these candidates possess sub-nanomolar affinity, superior pharmacokinetics, and distinct selectivity for ACVR2A . The study highlights their robust in vivo efficacy in reducing fat mass while enhancing muscle grip strength, validating their therapeutic potential for metabolic and muscle-wasting conditions.
Key Insights
This research presents critical preclinical validation data for novel anti-ACVR2A therapeutic candidates:
- Innovative Discovery: Utilizes the HUGO-Ab-eKO transgenic mouse platform to overcome >99% sequence homology, generating fully human antibodies.
- Enhanced Selectivity: Surface Plasmon Resonance (SPR) confirms sub-nanomolar binding affinity and superior selectivity for ACVR2A over ACVR2B.
- Potent Pathway Blockade: Reporter gene assays demonstrate dose-dependent inhibition of both ACVR2A-ALK4 and ACVR2A-ALK7 signaling pathways.
- Superior Pharmacokinetics: Lead candidates exhibit significantly extended half-lives and higher systemic exposure (AUC) in wild-type murine models.
- Dual Functional Benefits: Demonstrates robust in vivo efficacy by reducing fat mass in DIO mice and improving grip strength in SCID models.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
